Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome - Contacts and Locations

Home

Study Topics

Glossary


	Full Text View


	Tabular View


	Contacts and Locations


	No Study Results Posted


	Related Studies

Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome

This study has been terminated.

Study NCT00092287. Last updated on February 25, 2008. Information provided by Ipsen

Please refer to this study by its ClinicalTrials.gov identifier: NCT00092287

Locations


United States, Florida
	Larry Kvols, MD
	Tampa, Florida, United States, 33612

Sponsors and Collaborators

Ipsen

Investigators


Study Director:	France Catus, MD	Ipsen